Abd Assalam Qannus

Interests

No activities entered.

Courses

No activities entered.

Scholarly Contributions

Journals/Publications

• Al-Obaidi, M. M., Gungor, A. B., Nematollahi, S., Zangeneh, T. T., Bedrick, E. J., Johnson, K. M., Low-Adegbija, N. E., Alam, R., Rangan, P., William Heise, C., Ariyamuthu, V. K., Shetty, A., Qannus, A. A., Murugapandian, S., Ayvaci, M. M., Anand, P. M., & Tanriover, B. (2022). Effectiveness of Casirivimab-Imdevimab Monoclonal Antibody Treatment Among High-Risk Patients With Severe Acute Respiratory Syndrome Coronavirus 2 B.1.617.2 (Delta Variant) Infection. Open forum infectious diseases, 9(7), ofac186.
  More info

  Real-world data on the effectiveness of neutralizing casirivimab-imdevimab monoclonal antibody (Cas-Imd mAb) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among high-risk patients may inform the response to future SARS-CoV-2 variants.
• Tanriover, B., Anand, P. M., Ayvaci, M., Murugapandian, S., Qannus, A. A., Shetty, A., ARIYAMUTHU, V. K., Heise, C. W., Rangan, P., Alam, R., Nicole, A., Johnson, K., Bedrick, E. J., Zangeneh, T. T., Nematollahi, S., Gungor, A. b., & Al-Obaidi, M. (2022).

  Effectiveness of Casirivimab-Imdevimab Monoclonal Antibody Treatment Among High-Risk Patients With Severe Acute Respiratory Syndrome Coronavirus 2 B.1.617.2 (Delta Variant) Infection

  . Open forum infectious diseases.
• Tanriover, B., Tanriover, B., Anand, P. M., Anand, P. M., Ayvaci, M., Ayvaci, M., Murugapandian, S., Murugapandian, S., Qannus, A. A., Qannus, A. A., Shetty, A., Shetty, A., ARIYAMUTHU, V. K., ARIYAMUTHU, V. K., Heise, C. W., Heise, C. W., Rangan, P., Rangan, P., Alam, R., , Alam, R., et al. (2022). Effectiveness of Casirivimab-Imdevimab Monoclonal Antibody Treatment Among High-Risk Patients With Severe Acute Respiratory Syndrome Coronavirus 2 B.1.617.2 (Delta Variant) Infection. Open forum infectious diseases.
• Jurgensen, A., Qannus, A. A., & Gupta, A. (2020). Cognitive Function in Kidney Transplantation. Current transplantation reports, 7, 145-153.
  More info

  Cognitive impairment is common in kidney transplant recipients and affects quality of life, graft survival, morbidity, and mortality. In this review article we discuss the epidemiology, diagnosis, pathophysiology and future directions for cognitive impairment in kidney transplantation. We describe the potential role of pre-transplant cognition, immunosuppression and peri-transplant factors in post -transplant cognitive impairment.
• Qannus, A. A., Jurgensen, A., & Gupta, A. (2020). Cognitive Function in Kidney Transplantation.. Current transplantation reports, 7(3), 145-153. doi:10.1007/s40472-020-00284-0
  More info

  Cognitive impairment is common in kidney transplant recipients and affects quality of life, graft survival, morbidity, and mortality. In this review article we discuss the epidemiology, diagnosis, pathophysiology and future directions for cognitive impairment in kidney transplantation. We describe the potential role of pre-transplant cognition, immunosuppression and peri-transplant factors in post -transplant cognitive impairment..A majority of patients with kidney transplant have cognitive impairment. Cognitive impairment affects both pre-transplant evaluation and post-transplant outcomes. Failure to identify patients with cognitive impairment can withhold appropriate care and timely intervention..Cognitive impairment is common in kidney transplant and affects outcomes. Studies addressing modifiable risk factors and possible interventions to slow cognitive decline in patients with kidney disease are needed.
• Kfoury, H., Mubarak, M., Qannus, A. A., Alshareef, M., Alharbi, J., Alghurair, H., Bin Omair, A., Alshamlan, N., Raddaoui, L., & Alkhalidi, H. (2018). The histological spectrum of tubulo-reticular inclusion positive renal biopsies: a tertiary hospital experience and review of the literature. Ultrastructural pathology, 42(4), 365-368.
  More info

  To identify the underlying diseases with TRI-positive kidney biopsies, and describe the histological pattern and spectrum of TRI-positive kidney biopsies.
• Koubar, S. H., Qannus, A. A., Medawar, W., & Abu-Alfa, A. K. (2018). Hungry bone syndrome two weeks after starting cinacalcet: a call for caution. CEN case reports, 7(1), 21-23.
  More info

  Cinacalcet is an effective and safe alternative to parathyroidectomy in end stage renal disease (ESRD) patients with secondary hyperparathyroidism. Hypocalcemia is a known complication of treatment that is usually readily reversible upon discontinuation of the drug. It rarely manifests severely and symptomatically requiring hospital admission. We present the case of a 55 year old man with severe, symptomatic and prolonged hypocalcemia that occurred 2 weeks after starting cinacalcet. Cinacalcet induced a state of pharmacological parathyroidectomy with subsequent hungry bone syndrome. Serum calcium returned to normal range after 4 weeks of stopping the drug while receiving high doses of elemental calcium and vitamin D receptor activation therapy (VDRA).
• El Cheikh, J., Otrock, Z. K., Qannus, A. A., Kharfan-Dabaja, M. A., & Bazarbachi, A. (2016). Risk-Adapted Approach to HLA-Matched Sibling Hematopoietic Cell Allografting: Impact of Adjusting Conditioning Intensity and Integrating Post-Transplant Therapeutic Interventions. Clinical lymphoma, myeloma & leukemia, 16(5), 304-10.
  More info

  Optimizing conditioning and post-transplant intervention may reduce non-relapse mortality and relapse, improving survival after allogeneic hematopoietic cell transplantation (allo-HCT).